Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Innate Pharma to participate in the D. Boral Capital Global Conference

April 23, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that...

Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

April 17, 2026

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and...

Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026

April 13, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) will hold its Annual General Meeting of shareholders (“ AGM ”) at 10:30 a.m. CEST on May 21, 2026, at its...

Number of shares and voting rights of Innate Pharma as of April 9, 2026

April 13, 2026

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Innate Pharma to present at the AACR 2026 Oncology Industry Partnering Event

April 8, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering...

Innate Pharma to participate in the Kempen Life Sciences conference

April 3, 2026

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) And 2025 Form 20-f Annual Report

April 2, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the filing of its 2025 Universal Registration Document (Document d’enregistrement universel) for...

Innate Pharma reports full year 2025 financial results and business update

March 26, 2026

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation...

Innate Pharma announces conference call and webcast for full year 2025 financial results

March 19, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m...